Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | CMO, Hematology | December 14, 2021 | December 16, 2021 |
| Prelude Therapeutics IncPRLD · Entity 5561 | President, CMO | October 04, 2025 | October 07, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date December 14, 2021 · Filed December 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-12-14 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 2 · 2021-12-14 · Exercise / conversion · Acquired 1,500 · Balance 1,500 F1: Each American Depositary Share represents 13 Ordinary Shares. Row 3 · 2021-12-14 · Sale · Disposed 300 · Balance 1,200 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 4 · 2021-12-14 · Sale · Disposed 300 · Balance 900 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 5 · 2021-12-14 · Sale · Disposed 500 · Balance 400 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 6 · 2021-12-14 · Sale · Disposed 100 · Balance 300 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. Row 7 · 2021-12-14 · Sale · Disposed 200 · Balance 100 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 8 · 2021-12-14 · Sale · Disposed 100 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 · Expires 2029-06-04 | Direct | 211,276 |
Reported balance
After 2021-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-14 · Exercise / conversion · Disposed 19,500 · Balance 211,276 F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 160,055 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 160,055 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.
Prelude Therapeutics Inc
Report date October 04, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,917 |
Ending reported balance
After 2025-10-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-04 · Exercise / conversion · Acquired 9,375 · Balance 90,272 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Row 2 · 2025-10-04 · Tax withholding · Disposed 3,355 · Balance 86,917 F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,750 |
Reported balance
After 2025-10-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-04 · Exercise / conversion · Disposed 9,375 · Balance 18,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001213900-26-069246 · marketforms-73183.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| October 04, 2025 Filed Oct 7, 2025 11:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001683913-25-000004 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| October 04, 2025 Filed Oct 7, 2025 11:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,355 | $1.47 | $4,931.85 |
DisclosureSEC source: 0001683913-25-000004 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,917 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| October 04, 2025 Filed Oct 7, 2025 11:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683913-25-000004 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| July 04, 2025 Filed Jul 8, 2025 20:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005346 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| July 04, 2025 Filed Jul 8, 2025 20:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,355 | $0.79 | $2,663.53 |
DisclosureSEC source: 0001562180-25-005346 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,897 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| July 04, 2025 Filed Jul 8, 2025 20:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-005346 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001213900-25-054284 · marketforms-69814.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003036 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,355 | $0.68 | $2,264.63 |
DisclosureSEC source: 0001562180-25-003036 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,877 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-003036 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:31 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000956 · primarydocument.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 04, 2025 Filed Jan 7, 2025 21:15 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000237 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| January 04, 2025 Filed Jan 7, 2025 21:15 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,859 | $1.39 | $5,364.01 |
DisclosureSEC source: 0001562180-25-000237 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,857 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| January 04, 2025 Filed Jan 7, 2025 21:15 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-000237 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 20:10 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007253 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 20:10 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,349 | $2.00 | $6,698.00 |
DisclosureSEC source: 0001562180-24-007253 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,341 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 20:10 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-007253 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| July 04, 2024 Filed Jul 8, 2024 20:02 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005641 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date Read SEC document |
| July 04, 2024 Filed Jul 8, 2024 20:02 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,347 | $3.60 | $12,049.20 |
DisclosureSEC source: 0001562180-24-005641 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,315 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| July 04, 2024 Filed Jul 8, 2024 20:02 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-005641 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-24-051377 · marketforms-66260.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003347 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,347 | $4.74 | $15,864.78 |
DisclosureSEC source: 0001562180-24-003347 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,287 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 20:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003347 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:01 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002130 · primarydocument.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 22:00 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000338 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,375 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 22:00 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,844 | $3.77 | $14,491.88 |
DisclosureSEC source: 0001562180-24-000338 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,259 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 22:00 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-000338 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 13:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-007230 · primarydocument.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 13:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-007230 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| July 04, 2023 Filed Jul 6, 2023 20:35 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041553 · doc4.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,125 Underlying: Common Stock · 9,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| July 04, 2023 Filed Jul 6, 2023 20:35 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Tax withholdingCommon Stock | 3,242 | $4.65 | $15,075.30 |
DisclosureSEC source: 0001209191-23-041553 · doc4.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,353 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. Read SEC document |
| July 04, 2023 Filed Jul 6, 2023 20:35 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 9,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041553 · doc4.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001213900-23-047466 · ownership.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| April 06, 2023 Filed Apr 6, 2023 22:19 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | SaleCommon Stock | 13,280 | $6.12 | $81,273.60 |
DisclosureSEC source: 0001562180-23-003481 · primarydocument.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,220 F2 · kind: Represents the aggregate number of shares sold by the reporting person as a result of a mandatory sale to cover taxes and fees due upon the release and settlement of the RSUs. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 22:19 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionRestricted Stock Unit · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003481 · primarydocument.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSUs") represents a contingent right to receive one share of Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 22:19 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-003481 · primarydocument.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSUs") represents a contingent right to receive one share of Issuer's Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-23-001167 · primarydocument.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001213900-22-031996 · ownership.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantRestricted Stock Unit · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027196 · doc4.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. F3 · derivative.expiration_date: The RSUs shall vest as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:46 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 460,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001209191-22-027196 · doc4.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · President, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,000 Underlying: Common Stock · 460,000 shares Expires 2032-04-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on April 4, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · derivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,276 Underlying: Ordinary Shares · 19,500 shares Expires 2029-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $284.52 | $28,452.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $281.64 | $56,327.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $278.79 | $27,879.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $278.21 | $139,106.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $276.95 | $83,085.99 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $274.54 | $82,361.01 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,500 | $119.96 | $179,940.00 |
DisclosureSEC source: 0001651308-21-000255 · wf-form4_163969500095782.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.